Safety and Efficacy of Deucravacitinib in Japanese Patients With Moderate to Severe Plaque Psoriasis: 5-Year Analysis of the Phase 3 POETYK PSO-1, PSO-4, and Long-Term Extension Trials

By afschroeder • August 7, 2026

Okubo Y, Morita A, Tada Y, Imafuku S, Armstrong AW, Blauvelt A, Vaile J, Popmihajlov Z, Li J, Sawant R, Habiro K, Tsuritani K, Ohtsuki M. Safety and Efficacy of Deucravacitinib in Japanese Patients With Moderate to Severe Plaque Psoriasis: 5-Year Analysis of the Phase 3 POETYK PSO-1, PSO-4, and Long-Term Extension Trials. J Dermatol. 2026 Aug 5. doi: 10.1111/1346-8138.70392. Epub ahead of print. PMID: 42557591.

Tags: Dermatology, deucravacitinib, long‐term, phase 3, psoriasis, Publications, safety, tyrosine kinase 2 inhibitor

Related Posts

Multicytokine-based transcriptome-wide association study for 7 inflammatory skin disorders identifies candidate causal genes in keratinocytes

Zhang H, Patrick MT, Sarkar MK, Bogle R, Li Q, Uppala R, Perez White BE, Petukhova L, Dand N, Stuart PE, Christiano AM, Simpson MA,[...]

In search of a cure for pemphigus

Kasperkiewicz M. In search of a cure for pemphigus. Br J Dermatol. 2026 Aug 6:ljag326. doi: 10.1093/bjd/ljag326. Epub ahead of print. PMID: 42557880.

Deucravacitinib 5-Year Safety and Efficacy Results in Plaque Psoriasis: A Phase 3 Open-Label Extension of Randomized Clinical Trials

Armstrong AW, Lebwohl M, Warren RB, Morita A, Paul C, Thaçi D, Augustin M, Puig L, Daamen C, Li J, Alió A, Aggrey-Amable A, Scotto[...]